Page last updated: 2024-12-08

nsc 680410

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

NSC 680410: a bcr/abl kinase inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID387042
CHEMBL ID203695
SCHEMBL ID182500
MeSH IDM0357743

Synonyms (27)

Synonym
1-adamantyl 4-[(2,5-dihydroxyphenyl)methylamino]benzoate
1-adamantyl 4-((2,5-dihydroxybenzyl)amino)benzoate
smr001565882
adaphostin
NCI60_028675
HSCI1_000103
benzoic acid,5-dihydroxyphenyl)methyl]amino]-, tricyclo[3.3.1.13,7]dec-1-yl ester
benzoic acid,5-dihydroxyphenyl)methyl]amino]-,1-adamantyl ester
nsc-680410
241127-58-2
mls002702320 ,
nsc680410
ag 957, adamantyl ester
nsc 680410
CHEMBL203695
FT-0661424
benzoic acid,4-[[(2,5-dihydroxyphenyl)methyl]amino]-, tricyclo[3.3.1.13,7]dec-1-yl ester
SCHEMBL182500
AKOS024457768
DTXSID50327719
adaphostin, >=98% (hplc)
J-015348
MS-26598
AC-36936
HY-103275
CS-0026800
ADAMANTAN-1-YL 4-((2,5-DIHYDROXYBENZYL)AMINO)BENZOATE ,

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with NSC 680410 alone produced no weight changes and increased the median survival to 133%, whereas treatment with NSC680410 plus Flt-1/Fc chimera increased survival to 142% over control."( In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines.
Avramis, IA; Avramis, VI; Christodoulopoulos, G; Gonzalez-Gomez, I; Laug, WE; McNamara, G; Sausville, EA; Suzuki, A, 2002
)
0.89

Dosage Studied

ExcerptRelevanceReference
" In mice and dogs dosed with adaphostin, plasma concentrations of the compound decreased rapidly."( Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Covey, JM; Grossi, I; Hill, DL; Li, M; Peggins, J; Stinson, S; Veley, K; Wang, H; Zhang, R, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
acid sphingomyelinaseHomo sapiens (human)Potency281.838014.125424.061339.8107AID504937
Nrf2Homo sapiens (human)Potency3.54810.09208.222223.1093AID624171
glp-1 receptor, partialHomo sapiens (human)Potency28.18380.01846.806014.1254AID624417
TDP1 proteinHomo sapiens (human)Potency1.84780.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
hypothetical protein, conservedTrypanosoma bruceiPotency25.11890.223911.245135.4813AID624173
regulator of G-protein signaling 4Homo sapiens (human)Potency89.12510.531815.435837.6858AID504845
67.9K proteinVaccinia virusPotency7.29230.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency14.58100.005210.865235.4813AID686970
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency17.78280.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency70.79460.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency29.09290.004611.374133.4983AID624297
VprHuman immunodeficiency virus 1Potency25.11891.584919.626463.0957AID651644
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency14.70950.058010.694926.6086AID602310; AID651813
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency14.09600.025911.239831.6228AID602313; AID651815
Glycoprotein hormones alpha chainHomo sapiens (human)Potency3.54814.46688.344810.0000AID624291
Alpha-synucleinHomo sapiens (human)Potency19.95260.56239.398525.1189AID652106
Guanine nucleotide-binding protein GHomo sapiens (human)Potency6.30961.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
photoreceptor-specific nuclear receptorHomo sapiens (human)IC50 (µMol)4.08900.03742.93408.9620AID624394
transactivating tegument protein VP16 [Human herpesvirus 1]Human alphaherpesvirus 1 (Herpes simplex virus type 1)IC50 (µMol)11.55900.94604.70169.4870AID624395
Cyclin-dependent kinases regulatory subunit 1Homo sapiens (human)IC50 (µMol)36.00002.18002.18002.1800AID1413233
S-phase kinase-associated protein 2Homo sapiens (human)IC50 (µMol)36.00002.18002.18002.1800AID1413233
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein HSP 90-alpha isoform 2Homo sapiens (human)AC505.14700.19503.667918.6960AID540270
heat shock protein 90, putativePlasmodium falciparum 3D7AC508.91100.19504.992098.5000AID540268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (113)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
regulation of DNA-templated transcriptionCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
mitotic cell cycle phase transitionCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
fibroblast proliferationCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
cell divisionCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
regulation of mitotic cell cycleCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of apoptotic processS-phase kinase-associated protein 2Homo sapiens (human)
G1/S transition of mitotic cell cycleS-phase kinase-associated protein 2Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathwayS-phase kinase-associated protein 2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processS-phase kinase-associated protein 2Homo sapiens (human)
innate immune responseS-phase kinase-associated protein 2Homo sapiens (human)
defense response to virusS-phase kinase-associated protein 2Homo sapiens (human)
protein K63-linked ubiquitinationS-phase kinase-associated protein 2Homo sapiens (human)
protein K48-linked ubiquitinationS-phase kinase-associated protein 2Homo sapiens (human)
positive regulation of protein polyubiquitinationS-phase kinase-associated protein 2Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationS-phase kinase-associated protein 2Homo sapiens (human)
G2/M transition of mitotic cell cycleS-phase kinase-associated protein 2Homo sapiens (human)
SCF-dependent proteasomal ubiquitin-dependent protein catabolic processS-phase kinase-associated protein 2Homo sapiens (human)
regulation of cell cycleS-phase kinase-associated protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
histone bindingCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
ubiquitin bindingCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
protein kinase bindingCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
cyclin-dependent protein serine/threonine kinase activator activityCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
protein bindingS-phase kinase-associated protein 2Homo sapiens (human)
identical protein bindingS-phase kinase-associated protein 2Homo sapiens (human)
ubiquitin-like ligase-substrate adaptor activityS-phase kinase-associated protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
nucleoplasmCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
SCF ubiquitin ligase complexCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
cyclin-dependent protein kinase holoenzyme complexCyclin-dependent kinases regulatory subunit 1Homo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
nucleoplasmS-phase kinase-associated protein 2Homo sapiens (human)
nucleolusS-phase kinase-associated protein 2Homo sapiens (human)
cytosolS-phase kinase-associated protein 2Homo sapiens (human)
SCF ubiquitin ligase complexS-phase kinase-associated protein 2Homo sapiens (human)
cytosolS-phase kinase-associated protein 2Homo sapiens (human)
nucleusS-phase kinase-associated protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1413233Inhibition of GST-tagged SKP2 (unknown origin)/His6-tagged CKS1 (unknown origin) expressed in Escherichia coli protein-protein interaction after 1 hr by Alpha screen assay2018MedChemComm, Jul-01, Volume: 9, Issue:7
Chemical probes of Skp2-mediated p27 ubiquitylation and degradation.
AID1768529Induction of ROS generation in human Jurkat cells at 1 uM measured after 2 hrs by DCFH-DA staining based flourescence assay relative to H2O22021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
AID1768530Antagonistic cytotoxicity against human Jurkat cells assessed as decrease in cell viability at 0.1 to 25 uM measured after 72 hrs in presence of vorinostat2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
AID1768525Cytotoxicity against human Jurkat cells assessed as cell growth inhibition measured after 72 hrs by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
AID1768526Cytotoxicity against human A549 cells assessed as cell growth inhibition measured after 72 hrs by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
AID1768528Cytotoxicity against human KPL-4 cells assessed as cell growth inhibition measured after 72 hrs by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
AID261688Activity against NCI60 cell line xenograft in nude mouse by HF assay2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
AID1768532Half life in human serum incubated up to 24 hrs by HPLC analysis2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
AID261687Antiproliferative activity against NCI60 cell line2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Assessment of in vitro and in vivo activities in the National Cancer Institute's anticancer screen with respect to chemical structure, target specificity, and mechanism of action.
AID1768527Cytotoxicity against human Caco-2 cells assessed as cell growth inhibition measured after 72 hrs by CCK8 assay2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Synthesis and biological evaluation of platensic alcohol as an adamantane surrogate in antitumor drug lead adaphostin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's26 (74.29)29.6817
2010's7 (20.00)24.3611
2020's2 (5.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (94.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]